|
Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study
Jul 31, 2026 Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab Jul 31, 2026 Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide Jul 31, 2026 Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab Jul 31, 2026 Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide Jul 31, 2026 High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation Jul 30, 2026 Dexamethasone-Free Antiemetic Prophylaxis for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: A Multicenter, Phase III, Noninferiority Trial (CIVIC POD) Jul 30, 2026 Limiting Dexamethasone Exposure With Highly Emetogenic Chemotherapy Regimens: Is the Verdict In? Jul 30, 2026 Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial Jul 30, 2026 Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL Jul 29, 2026 Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial Jul 29, 2026 COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer Jul 29, 2026 Rethinking Regulatory Protections for Accelerated Approvals With Supplementary Indications Jul 29, 2026 He Was Always There Jul 28, 2026 Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial Jul 27, 2026 SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer Jul 27, 2026 Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer Jul 27, 2026 Time-Varying Effects of Copy Number Alteration Clustering: Methodologic Concerns in Survival Analysis of Relapsed/Refractory Germ Cell Tumors Jul 27, 2026 Anti-TIGIT in PD-L1–High Advanced Non–Small Cell Lung Cancer: Insights From SKYSCRAPER-01 and the Path Forward Jul 27, 2026 Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801) Jul 27, 2026 |
The Patient Who Could Not Die Journal of Clinical Oncology, Volume 44, Issue 28, Page 2745-2747, October 2026. <br/> 2026-10-01T07:00:00Z Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy Journal of Clinical Oncology, Volume 44, Issue 28, Page 2700-2713, October 2026. <br/> 2026-10-01T07:00:00Z Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial Journal of Clinical Oncology, Volume 44, Issue 28, Page 2662-2669, October 2026. <br/> 2026-10-01T07:00:00Z Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2 Journal of Clinical Oncology, Volume 44, Issue 28, Page 2680-2689, October 2026. <br/> 2026-10-01T07:00:00Z Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma Journal of Clinical Oncology, Volume 44, Issue 28, Page 2690-2699, October 2026. <br/> 2026-10-01T07:00:00Z Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0 Journal of Clinical Oncology, Volume 44, Issue 28, Page 2725-2744, October 2026. <br/> 2026-10-01T07:00:00Z Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study Journal of Clinical Oncology, Volume 44, Issue 28, Page 2670-2679, October 2026. <br/> 2026-10-01T07:00:00Z Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia Journal of Clinical Oncology, Volume 44, Issue 28, Page 2714-2724, October 2026. <br/> 2026-10-01T07:00:00Z Resistance to Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators Journal of Clinical Oncology, Volume 44, Issue 28, Page 2657-2661, October 2026. <br/> 2026-10-01T07:00:00Z Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing? Journal of Clinical Oncology, Volume 44, Issue 28, Page 2748-2748, October 2026. <br/> 2026-10-01T07:00:00Z Optimizing Outcomes After Pediatric Haploidentical Donor Transplant: Role of Graft-Versus-Host Disease Prophylaxis? Journal of Clinical Oncology, Volume 44, Issue 28, Page 2751-2752, October 2026. <br/> 2026-10-01T07:00:00Z Erratum: Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2 Journal of Clinical Oncology, Volume 44, Issue 28, Page 2756-2756, October 2026. <br/> 2026-10-01T07:00:00Z Reply to: Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing? Journal of Clinical Oncology, Volume 44, Issue 28, Page 2749-2750, October 2026. <br/> 2026-10-01T07:00:00Z Reply to: Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing? Journal of Clinical Oncology, Volume 44, Issue 28, Page 2750-2751, October 2026. <br/> 2026-10-01T07:00:00Z Reply to: Optimizing Outcomes After Pediatric Haploidentical Donor Transplant: Role of Graft-Versus-Host Disease Prophylaxis? Journal of Clinical Oncology, Volume 44, Issue 28, Page 2753-2755, October 2026. <br/> 2026-10-01T07:00:00Z Targeting ErbB-Family Receptors in Small Cell Lung Cancer: Clinical Activity and an Unresolved Mechanism Journal of Clinical Oncology, Volume 44, Issue 28, Page 2653-2656, October 2026. <br/> 2026-10-01T07:00:00Z |
Giredestrant plus Everolimus in Advanced Breast Cancer
In ER-positive, HER2-negative advanced breast cancer, giredestrant, an ER degrader and full ER antagonist, plus everolimus led to longer progression-free survival than standard endocrine therapy–everolimus; safety was similar. 2026-10-01
Joint Clinical Assessments — A New Chapter in European Pharmaceutical Policy A new European Union regulation introduces a centralized clinical assessment process for comparing the effectiveness and safety of new medicines with those of the standards of care in various countries. 2026-10-01
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma In a phase 1 study of anito-cel, a CAR T-cell therapy, for relapsed or refractory myeloma, all 38 patients had a response. Severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome were rare. 2026-09-24
Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome Persons with Wiskott–Aldrich syndrome were treated with an autologous gene therapy consisting of hematopoietic stem and progenitor cells transduced ex vivo with a lentiviral vector encoding WAS complementary DNA. 2026-09-24
Clinical Uses of Common Genetic Variants Associated with Common Diseases The authors review the ways common genetic variants, polygenic risk scores, and pharmacogenomic genotyping may be useful in the prevention of common diseases and the treatment of common diseases after diagnosis. 2026-09-24
Science behind the Study: Anito-cel for Multiple Myeloma The author describes the science behind a phase 1 study of anitocabtagene autoleucel, a CAR T cell that deploys a CAR with a novel synthetic antigen-binding domain, in patients with multiple myeloma. 2026-09-24
IARC Perspective on Lung Cancer Screening The 21st volume of the IARC Handbooks summarizes and evaluates evidence for the benefits and harms of lung cancer screening with low-dose CT or chest radiography and assesses tools and strategies to improve screening. 2026-09-24
A Cure Out of Most Patients’ Reach — Sickle Cell Disease in the Gene-Therapy Era Gene therapy can spare people with sickle cell disease from recurrent vaso-occlusive crises, but for the populations that bear most of the global burden of disease, there’s no pathway to such treatment. 2026-09-24
Cumulative Hematologic Morbidity and Outcomes in Shwachman–Diamond Syndrome In an international cohort of 865 patients, Shwachman–Diamond syndrome was associated with a high risk of myeloid cancer and poor survival. Early hematopoietic stem-cell transplantation for high-risk features had a potential benefit. 2026-09-24
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis In a trial of a blood-based multicancer early-detection test added to usual care, the incidence of stage III or IV cancer after three rounds of screening did not differ significantly from that with usual care alone. 2026-09-22
A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer The diagnosis of cancer at earlier stages is generally associated with improved survival. Detecting circulating tumor–derived cell-free DNA (cfDNA) is an established method of monitoring the response to therapy for many cancer types, particularly hematopoietic and metastatic cancers — which leads to the question of whether screening for cfDNA in... 2026-09-22
Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal In this planned interim analysis of a randomized trial, first surveillance colonoscopy at 5 years after the removal of high-risk adenomas was noninferior to first colonoscopy at 3 years for the incidence of colorectal cancer. 2026-09-17
Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia Among children with high-risk B-cell acute lymphoblastic leukemia, two cycles of blinatumomab led to a higher 4-year event-free survival than two cycles of chemotherapy (83.0% vs. 70.3%), with a lower risk of serious infection. 2026-09-17
Esophageal Cancer For patients with esophageal cancer, 5-year survival has improved in recent decades but rarely exceeds 20%. This review summarizes risk factors, screening, and treatment for the two main histologic types. 2026-09-17
Blinatumomab — A New Standard of Care in Acute Lymphoblastic Leukemia Research involving the treatment of pediatric acute lymphoblastic leukemia (ALL) established the paradigm for improving survival in cancer. In iterative clinical trials conducted by cooperative groups, long-term survival has improved from less than 10% to 90% owing to the use of improved multidrug regimens and treatment tailored to clinical and... 2026-09-17
Initial Screening for Colorectal Cancer This feature about colorectal cancer screening in a 46-year-old man offers a case vignette accompanied by two essays, one recommending screening by colonoscopy and the other supporting use of a stool-based test. 2026-09-17
Case 26-2026: A 62-Year-Old Woman with Memory Loss, Anhedonia, and Temporal Wasting A 62-year-old woman with a history of stroke and metastatic breast cancer that was being treated with immunomodulator therapy presented with memory loss, confabulation, anhedonia, ataxia, and weight loss. A diagnosis was made. 2026-09-17
When More Is Not Better — Colonoscopy Surveillance after High-Risk Adenomas Colonoscopy surveillance after the removal of adenomas is a cornerstone of the prevention of colorectal cancer. Guidelines in the United States and Europe have endorsed surveillance beginning at 3 years after the removal of advanced adenomas (defined as ≥1 adenoma with a diameter of ≥10 mm, high-grade dysplasia, or villous... 2026-09-17
Human Adenovirus B3–Induced Immune Thrombocytopenia and Thrombosis Virus-induced immune thrombocytopenia and thrombosis after HAdV-B3 infection supports a shared platelet factor 4–targeted immune mechanism linking natural adenovirus infection and adenoviral vector–associated disease. 2026-09-17
Colorectal Cancer Risk among Patients with Serrated Polyps In this prospective trial, patients with serrated polyps had a low 5-year risk of colorectal cancer (1.0%). 2026-09-17
|
|
|
| |||
|
[Editorial] Microplastics and cancer: a looming threat?
Microplastics are a growing global concern and have been linked to various health conditions. A study presented by Ilias Dimeas and colleagues at the 2026 European Respiratory Society conference found a higher burden of microplastics in the lungs of patients with lung cancer than in those without cancer. In the study, 70% of 100 people undergoing a bronchoscopy had detectable microplastics in at least one sample, and patients with lung cancer were more likely to have detectable microplastics in their samples than patients without lung cancer. Thu, 01 Oct 2026 00:00:00 -0700
[Comment] Exercise oncology: from trials and guidelines to routine clinical care In oncology practice, there are trade-offs between quality of life and survival for many therapies. Similar trade-offs exist for drug reimbursement based on therapeutic effectiveness, affected population, and cost. Fri, 04 Sep 2026 22:30:01 +0000
[Comment] Looking at cancer burden in Africa through a new lens Cancer remains a leading cause of death and disability globally, with a disproportionate rising burden in Africa.1,2 Effective policy response has been consistently hampered by fragmented and incomplete cancer surveillance data.3 For a long time, there has been an assumption that a global uniform framework for understanding cancer risk factors exists and is applicable universally.4 This concept of harmonised global data is plausible in well structured and well resourced health systems in which research and care systems are integrated—systems that exist mostly in high-income regions. Thu, 01 Oct 2026 00:00:00 -0700
[Comment] Personalised medicine in oncology: inequality aversion in a fast-moving field Personalised medicine has been shown to improve patient care and holds promise to further benefit treatment results. The Lancet Oncology Commission on accelerating equitable cancer genomics and precision oncology in health care and research provides an overview of state-of-the-art treatments and the situation in low-income and middle-income countries (LMICs). From targeted treatment using companion diagnostics, identifying targets to guide treatment decisions, to broad ‘omics testing in cancer of unknown primary and metastasised tumours, the field is vast and inequalities exist within and between countries. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Ethical priorities in global cancer genomics and precision oncology Amid the promise of cancer genomics and precision oncology lies complex and ethically weighty issues. Genomics and other ‘omics are undoubtedly transforming cancer care for thousands of patients annually, enabling better prognosis, access to treatments or trials, or informing relatives. Yet, these interventions overwhelmingly benefit people in high-income countries: they are failing to reach most patients with cancer who could benefit, and those who are reached could, for reasons including health system readiness or data representation and interpretation, receive no or marginal benefit to their care. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Inequities in access to precision oncology: shared challenges, unified blueprint Precision oncology has substantially changed the therapeutic landscape from a “one size fits all” approach to that of individualised (or personalised) treatments.1 The promise of precision oncology extends across the entire cancer continuum from prevention, early diagnosis, subtyping of tumours, treatment selection, risk-adapted therapies, development of novel anticancer medicines, and post-treatment surveillance.2 The Lancet Oncology Commission on accelerating equitable cancer genomics and precision oncology in health care and research focuses on the current challenges and practical solutions to faciliate wider implementation. Fri, 25 Sep 2026 03:10:27 +0000
[Comment] Beyond the evidence: why multistakeholder cooperation will determine whether cancer genomics reaches patients The Lancet Oncology Commission on accelerating equitable cancer genomics and precision oncology presents a worrying picture.1 While the number of precision oncology drugs continues to increase,2,3 access to testing and matched therapies remains profoundly unequal, research is concentrated in high-income countries (HICs) and populations of European ancestry, and expanding testing capacity has not always translated into proportionate population-level benefit. The Commission's survey of national cancer control programmes (NCCPs), conducted in collaboration with the Union for International Cancer Control and WHO International Agency for Research on Cancer (IARC) across 34 countries, found partial integration of genomics into most NCCPs, including in HICs. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Ecological neglect: critical oversight in precision oncology governance The Lancet Oncology Commission on accelerating equitable cancer genomics and precision oncology in health care and research1 examines the gap between the promise of precision oncology and its delivery across global health systems. Raffaella Casolino and colleagues argue that precision oncology has advanced with remarkable speed, yet its clinical impact and sustainability remain uneven, meaning that for much of the world, precision oncology remains just a promise. The authors argue that if the vision of precision oncology is to be realised, health systems need to generate, integrate, govern, and learn from data. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Affordability in the era of precision oncology Cancer drugs are increasingly unaffordable for health systems. Global spending on cancer drugs will reach US$441 billion by 2029.1 This 75% increase over 5 years cannot be explained by population ageing or changing prevalence alone. Instead, the price of cancer drugs is driving accelerated spending growth.2 Rising prices place considerable pressure on health systems, particularly when increased spending is not matched by commensurate improvements in patient health. Unfortunately, many expensive cancer drugs have highly uncertain safety and efficacy evidence at the time of market authorisation. Fri, 25 Sep 2026 03:10:03 +0000
[Comment] Counting who was not tested: artificial intelligence extraction of genomic and treatment data from hospital records The Lancet Oncology Commission on accelerating equitable access to cancer genomics and precision oncology provides an important framework defining indicators that health systems can and should measure.1 Operationalising these indicators, however, requires substantial data infrastructure. One indicator in the Commission's Precision Oncology Access Cascade defines the group of eligible patients who receive recommended genomic testing. The number of patients tested is relatively straightforward to obtain; however, the number meeting the guideline criteria is not because this information is usually recorded as unstructured narrative text rather than as a structured field. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Blank spaces on the map: genomics for global cancer research For most of the history of cancer genomics, the map of our knowledge has had blank spaces on it. In the Pan-Cancer Analysis of Whole Genomes, for example, roughly three quarters of donors were of European descent; samples from Latin American donors made up only about 1% of the large public repositories and samples from patients of Middle Eastern descent were almost entirely absent.1 Thu, 01 Oct 2026 00:00:00 -0700
[Comment] England's National Cancer Plan; ambition without accountability Publication of England's National Cancer Control Plan (NCCP) in February, 2026,1 marked a hard-won achievement, after years of advocacy from patients, clinicians, charities, parliamentarians, and The Lancet Oncology.2,3 The expectation was to address long-standing systemic issues in treatment delays and quality, workforce shortages, and inequalities; but hopes were quickly dashed.4 The plan had no real new money, no additional workforce capacity, no expansion of treatment infrastructure, no prioritisation, and no implementation strategy. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Re-evaluating aglatimagene in localised prostate cancer We read with great interest the Article by Theodore L DeWeese and colleagues detailing the results of the PrTK03 phase 3 trial, which evaluated the addition of aglatimagene besadenovec (CAN-2409) and valacyclovir to standard-of-care external beam radiation therapy (EBRT) for localised prostate cancer.1 We commend the investigators for executing this decade-spanning study. The biological premise—using an adenoviral vector to exert localised cytotoxicity of a systemically administered prodrug while stimulating a T-cell-mediated immune response—is scientifically sound. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Re-evaluating aglatimagene in localised prostate cancer – Authors' reply We thank Thomas Büttner and colleagues for their interest in our Article on the PrTK03 trial.1 In our trial, disease-free survival was the prospectively specified, US Food and Drug Administration-agreed primary endpoint under a Special Protocol Assessment, analysed in the intention-to-treat population and defined to include local failure, including positive biopsy, regional failure, distant metastasis, or death.1 The US Food and Drug Administration did not agree to use biochemical failure as a disease-free survival event. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC Leonardo Brunetti and colleagues’ post-hoc analysis of the PACIFIC trial in The Lancet Oncology addresses an important and clinically timely question: whether baseline exposure to proton pump inhibitors or antibiotics modifies the benefit of durvalumab after concurrent chemoradiotherapy in patients with unresectable stage III non-small-cell lung cancer.1 The observed association between proton pump inhibitor exposure and inferior progression-free and overall survival in the durvalumab group, but not in the placebo group, is thought provoking. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC I read with great interest the Article by Leonardo Brunetti and colleagues,1 which reported that baseline exposure to proton pump inhibitors was associated with substantially inferior progression-free and overall survival among patients receiving durvalumab after concurrent chemoradiotherapy in the PACIFIC trial, but not among those receiving placebo. The use of a randomised, placebo-controlled dataset to separate prognostic from predictive associations is a genuine advance over observational literature. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC Leonardo Brunetti and colleagues report an important post-hoc analysis of the PACIFIC trial,1 showing that baseline exposure to proton pump inhibitors, and to a lesser extent antibiotics, was associated with inferior survival outcomes following durvalumab, but not placebo, in patients with unresectable stage III non-small-cell lung cancer (NSCLC). The randomised placebo-controlled setting and differential analysis across the treatment group are major strengths. Nevertheless, proton pump inhibitor exposure itself was not randomised, and the clinical context in which proton pump inhibitors were prescribed could be crucial to interpretation. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC Leonardo Brunetti and colleagues report an association between proton pump inhibitor exposure and shorter overall survival among patients receiving consolidation durvalumab, but not placebo, in the PACIFIC trial, and propose gut dysbiosis as a potential underlying mechanism.1 We seek clarification on one aspect of the analysis and propose an alternative explanation. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC – Authors' reply We thank our colleagues for their thoughtful comments on our post-hoc analysis of PACIFIC.1 Their correspondence raises two issues: the definition of survival events and whether proton pump inhibitor exposure is causal or reflects its prescribing context. Thu, 01 Oct 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 181–90 Tang C, Sherry AD, Hwang H, et al. Lancet Oncol 2026; 27: 181–90—In this Article, in the Baseline castration sensitivity row of table 2, the data for patients who are castration resistant and those who are castration sensitive were reversed. This correction has been made to the online version as of Sept 3, 2026. Thu, 03 Sep 2026 22:30:00 +0000
[Corrections] Correction to Lancet Oncol 2026; 27: 1043–56 Brunetti L, Santo V, Pinato DJ, et al. Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial. Lancet Oncol 2026; 27: 1043–56—The appendix of this Article has been corrected as of Sept 28, 2026. Thu, 01 Oct 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 1077–93 Kudo M, Abou-Alfa GK, Ren Z, et al. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. Lancet Oncol 2026; 27: 1077–93—In this Article, sentence eight of the Findings in the Summary should have read ‘post-embolisation syndrome’. In the Outcomes section of the Methods, the disease control rate at 20 weeks explanation has been corrected. Thu, 01 Oct 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 1094–109 Le X, Passaro A, Zhao Y, et al. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2026; 27: 1094–109—In this Article, the second and third sentences of the ninth paragraph of the Results section should have read “The most common immune-related treatment-related adverse events of any grade in the ivonescimab plus chemotherapy group were hypothyroidism (18 [8%]) and hyperthyroidism (nine [4%]), and in the placebo plus chemotherapy group were rash (seven [3%]), alanine aminotransferase increased (seven [3%]), aspartate aminotransferase increased (six [3%]), and amylase increased (six [3%]). Thu, 01 Oct 2026 00:00:00 -0700
[News] Trump cuts childhood vaccine recommendations The US President Donald Trump has issued an executive order stressing “maximal parental choice” and cutting the number of childhood vaccines recommended by the federal government to 11 from 18. Thu, 20 Aug 2026 22:30:04 +0000
[News] Nigeria plans major expansion of radiotherapy capacity Africa's most populous country Nigeria plans to procure and install 35 additional linear accelerators (LINACs), substantially expanding its radiotherapy capacity. Six Cancer Centres of Excellence are also being developed, with centres in Katsina, Enugu, and Benin completed and commissioned. However, the new machines translating into wider access depends on availability of specialist staffing, maintenance, financing, and where the additional capacity is located. Thu, 20 Aug 2026 22:30:01 +0000
[News] Delays in cancer referrals and care lead to harm and missed diagnoses in England Late and missed diagnoses, delays in cancer care, and physical harm were partly caused by England's National Health Service (NHS) system for general practitioners (GPs) seeking specialist advice before patient referral to hospital, according to an investigation by the Health Services Safety Investigations Body (HSSIB). Thu, 27 Aug 2026 22:30:01 +0000
[News] Increased tobacco production and cigarette imports in Africa While tobacco-leaf production across the world declined by 19% between 2012 and 2024, it increased by 9% in Africa, according to a WHO analysis published on Aug 31, 2026. Moreover, during this period, there was a more than two-times increase in cigarette imports to Africa—from US$833 million to $1·77 billion. Thu, 10 Sep 2026 22:30:01 +0000
[News] 2026 World Conference on Lung Cancer Interim results from the phase 3 ARTEMIS-008 trial, presented by Jie Wang (Chinese Academy of Medical Sciences, Beijing, China), suggest risvutatug rezetecan, a B7-H3-directed antibody–drug conjugate (ADC), could be the new standard of care in relapsed small-cell lung cancer (SCLC). Patients were randomly assigned (1:1) to receive risvutatug rezetecan (8·0 mg/kg; n=230) or topotecan (1·2 mg/m2 on days 1–5; n=231) every 3 weeks. At a median follow-up of 12·2 months, overall survival (the primary endpoint) was significantly improved with risvutatug rezetecan compared with topotecan (18·5 vs 10·3 months; HR 0·46 [95% CI 0·35–0·62). Thu, 17 Sep 2026 22:30:02 +0000
[News] Kenya agrees major cuts to cancer drug prices The Kenyan Government has agreed a deal with Pfizer that could reduce the price of selected cancer medicines by seven times. Costs are expected to drop from as much as 1 million Kenyan Shillings (KSh; US$7725) to below KSh50 000 ($386) per treatment cycle for some drugs. The agreement covers nine cancers: breast, stomach, colorectal, lung, prostate, and oesophageal cancers, as well as leukaemia, lymphoma, and multiple myeloma. Thu, 17 Sep 2026 22:30:01 +0000
[News] Toxic dust around the World Trade Center On Sept 8, 2026, New York City authorities released more than 170 000 pages of documents showing that officials misled the public about toxic air quality levels after the Sept 11, 2001, attack that killed more than 2600 people at the World Trade Center (WTC). Health researchers say the documents contain little medical information that is new but confirm that carcinogens and toxins were present months after the attacks, exposing 400 000 people in lower Manhattan to smoke, dust, and combustion products. Thu, 17 Sep 2026 22:30:02 +0000
[Perspectives] Cancer's new anxiety: not a death sentence, but delay Throughout the history of cancer research, hyperbole has never been in short supply—whether it be Richard Nixon's war, Joe Biden's moonshot, or Cancer Research UK's 2023 declaration of a golden era. Driving such rhetoric has been the need to act against an enduring societal concern—cancer, the so-called Big C, society's number one fear. Thu, 01 Oct 2026 00:00:00 -0700
[Perspectives] Against cancer, not against dying: Ernest Becker in the oncology clinic When American cultural anthropologist Ernest Becker was awarded the 1974 Pulitzer Prize for his book, The Denial of Death, he had died of colorectal cancer only 2 months earlier. More than half a century later, the book feels almost uncomfortably contemporary in the oncology clinic. Although the book does not address cancer care directly, it speaks to what cancer reveals: mortality, and the symbolic structures we build to make that knowledge bearable. For Becker, identities, professions, institutions, religions, families, reputations, and achievements are ways in which the fragile self seeks continuity beyond finitude. Thu, 01 Oct 2026 00:00:00 -0700
[Perspectives] Sir Chris Hoy's Tour de 4 charity cycle ride returns Mention the name Chris Hoy and it's natural to picture the Olympic cyclist, who won six gold medals and one silver in Sydney, Athens, Beijing, and London between 2000 and 2012. Fans voted for him to be named as the BBC Sports Personality of the Year in 2008, and he was knighted by the late Queen Elizabeth in the 2009 New Year honours list. However, over the past 2 years, Hoy has become famous for a completely different reason. In October, 2024, he revealed that he had received a terminal diagnosis of stage-4 prostate cancer, which had spread to his bones. Sun, 06 Sep 2026 23:01:02 +0000
[Perspectives] Differing approaches to cancer at the Edinburgh Fringe “I had cancer a couple of years ago—I don’t like to talk about it,” grinned comedian Matt Forde during his show at the Edinburgh Festival Fringe, the world's largest arts festival, which took place in Edinburgh, UK, on Aug 7–31, 2026. With a sly grin at his audience, he added “I’m not going to use it to sell tickets for another sold out night in Edinburgh.” Forde, who is best known for his impressions of politicians, was diagnosed in July, 2023, with a chordoma, a very rare sarcoma at the base of his spine. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial Pembrolizumab plus chemotherapy followed by maintenance with pembrolizumab–olaparib showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy, suggesting that this regimen might have potential for patients with newly diagnosed BRCA non-mutated stage III–IV epithelial ovarian cancer. Mon, 07 Sep 2026 22:30:04 +0000
[Articles] Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis Our findings highlight the importance of infection control to achieve cancer prevention. Scientifically proven, but often underused, approaches include HPV and HBV vaccination; testing and treatment of HIV, H pylori, HBV, and HCV; safe injection practices; access to condoms and pre-exposure prophylaxis to prevent HIV transmission; and screening of precancerous lesions for HPV-driven cervical and anal cancer. Our findings also inform the investment cases for research and development for new prevention tools, most notably for EBV. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial Hypofractionated postmastectomy radiotherapy provided durable locoregional control with no increase in severe late adverse events compared with conventional fractionation, supporting its use as a more time-efficient option than conventional fractionated radiotherapy. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial Weekly PRO symptom monitoring was associated with meaningful improvement in long-term overall survival among patients with stage I–IV lung cancer. Median overall survival was 5 months longer in the intervention group than in the control group. These findings underscore the value of implementing PRO symptom monitoring within routine care for patients with lung cancer. Fri, 11 Sep 2026 22:30:01 +0000
[Articles] Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial OPTIMUM shows sustained progression-free survival and overall survival improvement with risk-stratified extended therapy, supporting implementation of molecular diagnostics and tailored treatment in patients with newly diagnosed high-risk multiple myeloma. Mon, 07 Sep 2026 22:30:01 +0000
[Articles] An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial The STAMINA lifestyle intervention meets best practice guidelines, can be implemented in NHS trusts in England, and offers clinicians a clear basis for identification and prescription of a supervised exercise and dietary advice intervention to mitigate negative effects associated with ADT. Fri, 04 Sep 2026 22:30:01 +0000
[Articles] Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era The CPI2 model, using 14 readily available clinical parameters, demonstrated improvement in discriminative accuracy compared with the IMDC model. This classification should be further validated in other trial and observational populations and be used to reanalyse heterogeneity of treatment effects of immune checkpoint inhibitor-based combination regimens in trials shaping the current and future treatment landscape. Wed, 09 Sep 2026 22:30:01 +0000
[Articles] Long-term exposure to wildfire-related PM2·5 and overall survival of older patients with lung cancer: a retrospective, registry-based cohort study Wildfire-related PM2·5 showed greater toxicity per unit exposure than non-wildfire PM2·5. As wildfire-related PM2·5 is the fastest-growing contributor to ambient air pollution, there is an urgent need for updated strategies to manage wildfires and mitigate their effects. Tue, 15 Sep 2026 22:30:01 +0000
[Articles] Burden of cancer in Africa, 1990–2023: a systematic analysis from the Global Burden of Disease Study 2023 Cancer is a growing contributor to the disease burden in Africa, with rising cases, deaths, and DALYs disproportionately affecting children, adolescents, and young adults. The increase in age-standardised mortality and DALY rates stands in sharp contrast to the ambitions of the Sustainable Development Goals for 2030 and the African Union Agenda 2063. Addressing this burden will require coordinated national and international action, with health-system strengthening and context-specific cancer-control strategies spanning prevention, early diagnosis, and treatment. Tue, 15 Sep 2026 22:30:01 +0000
[The Lancet Oncology Commission] Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission Cancer genomics and precision oncology are increasingly central to cancer care, but many health systems struggle to implement them equitably, effectively, and sustainably. This Commission defines the current global precision oncology landscape and analyses the scientific, structural, and health-system challenges shaping its delivery and impact. Findings indicate that access to cancer genomics and precision oncology remains profoundly unequal across and within countries, leaving millions of patients without guideline-indicated interventions each year. Fri, 25 Sep 2026 03:10:28 +0000
[Policy Review] Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population Cancer susceptibility testing is rapidly advancing beyond specialist genetics clinics into routine oncology and population-level genomics initiatives. This expansion positions germline pathogenic variants in cancer susceptibility genes and polygenic risk scores as crucial tools for precision prevention, surveillance, and early detection. However, implementation has outpaced the evidence needed to justify testing at scale, particularly in well populations. For a small number of first-wave genes—including BRCA1, BRCA2, MLH1, and MSH2—cancer risks are well established and downstream medical interventions are supported by substantial observational evidence, albeit with an absence of randomised trials. Fri, 25 Sep 2026 03:10:02 +0000
[Review] Cancer and the microbiome: from association to intervention The gut microbiome is increasingly recognised as a clinically modifiable determinant of efficacy and toxicity across systemic cancer therapies, with the most mature evidence in patients receiving immune checkpoint inhibitors (ICIs). The composition and function of intestinal microbes can influence treatment outcomes by affecting immune priming, antigen presentation, host–microbial co-metabolism, drug biotransformation, and epithelial barrier integrity. In melanoma, non-small-cell lung cancer, and renal cell carcinoma, higher microbial diversity, ecological stability, and enrichment of immunostimulatory pathways have been associated with improved ICI response and survival. Thu, 01 Oct 2026 00:00:00 -0700
[Clinical Picture] Not all thoracic micronodules are metastases A 58-year-old female, lifelong non-smoker with history of Parkinson's disease, presented with a palpable right breast lump to the Odette Cancer Centre at Sunnybrook Health and Sciences Centre (Toronto, ON, Canada) in April, 2024, and was diagnosed with right-sided oestrogen receptor-positive, HER2-positive breast cancer (cT3N0). She received neoadjuvant dose dense doxorubicin–cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab. Lumpectomy and sentinel lymph node biopsy was performed revealing a pathological complete response. Thu, 01 Oct 2026 00:00:00 -0700
|
All‐oral regimen approved for older patients with AML who are ineligible for intensive chemotherapy
Tue, 29 Sep 2026 01:37:22 -0700 Study raises important questions about the clinical utility of multicancer early detection testing Tue, 29 Sep 2026 01:29:58 -0700 Tile‐based radiation therapy may be new standard of care for patients with surgical brain metastases Tue, 29 Sep 2026 01:26:32 -0700 Trends in sociodemographic factors associated with human papillomavirus vaccine hesitancy in the United States: 2010–2022 This study emphasizes the need to dispel misconceptions and create awareness about HPV vaccine across all strata of the society. Mon, 28 Sep 2026 00:00:00 -0700 Progression‐free survival and overall survival in the first‐line treatment of BRCA wild‐type advanced epithelial ovarian cancer: An analysis of patient‐level data pooled from historical clinical trials Mon, 28 Sep 2026 00:00:00 -0700 Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025 Mon, 28 Sep 2026 00:00:00 -0700 External validation of the NADIR model for early prostate‐specific antigen response prediction in enzalutamide‐treated metastatic hormone‐sensitive prostate cancer: An analysis of the ARCHES trial The NADIR model demonstrates robust and reproducible discrimination, calibration, and prognostic stratification in a distinct ARPI‐treated mHSPC cohort, supporting its potential utility for early response risk stratification and trial enrichment pending prospective validation of model‐guided treatment adaptation. Fri, 25 Sep 2026 00:00:00 -0700 Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis Cilta‐cel remains effective in frail RRMM, but frailty is associated with reduced survival and increased toxicity, supporting tailored CAR‐T strategies. Thu, 24 Sep 2026 00:00:00 -0700 Outcome after first relapse post‐immunochemotherapy in older adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia: A GRAALL study These results indicate that salvage regimen should be proposed in this context, allowing 50% of patients to achieve CR2 and have better survival. Thu, 24 Sep 2026 00:00:00 -0700 Toward a globally integrated histologic risk classification of pretreated Wilms tumor Thu, 24 Sep 2026 00:00:00 -0700 Progression‐free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta‐analysis Thu, 24 Sep 2026 00:00:00 -0700 Recommendations of the American Cancer Society workshop on design, conduct, analysis, and reporting of multicancer early detection trials with late‐stage incidence end points and post‐trial ongoing evaluation—The Peachtree Consensus Trials with late‐stage incidence end points that are conducted using these principles should support the development of evidence‐based screening guidelines as well as the creation of accessible data resources for observational and modeling studies. Wed, 23 Sep 2026 00:00:00 -0700 Annual Report to the Nation on the Status of Cancer, featuring 21st century progress against lung cancer Cancer incidence was stable among males but increased slowly among females. Cancer mortality continued to decline, largely because of sustained progress against lung cancer. Tue, 22 Sep 2026 00:00:00 -0700 Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial These findings suggest oral VitC as a safe, biologically active intervention in patients with early‐stage myeloid malignancies and precursor conditions. A phase 3 trial is warranted. Mon, 21 Sep 2026 00:00:00 -0700 Outcomes of adult patients with Li‐Fraumeni syndrome and myeloid neoplasms Fri, 18 Sep 2026 00:00:00 -0700 Issue Information Thu, 17 Sep 2026 01:48:12 -0700 Impact of post‐chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children’s Oncology Group AREN0532, AREN0533, and AREN03B2 studies Thu, 17 Sep 2026 00:00:00 -0700 |
||
|
| |||
|
[Editorial] Personalising AML treatment: beyond age and fitness
Over the past couple of decades, the number of treatment options for patients with acute myeloid leukaemia has accelerated; however, most patients still do not survive long-term, with 5-year overall survival around 30%. For younger and functionally fit patients, the predominant front-line therapy has remained unchanged for half a century: intensive induction chemotherapy that includes cytarabine and anthracyclines (the 7+3 regimen). For older patients or those not able to undergo intensive chemotherapy, a combination of hypomethylating agent and venetoclax is now the standard front-line therapy, spearheaded by the VIALE-A trial in 2020. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia Nicolò Peccatori and colleagues provide evidence for inotuzumab ozogamicin in paediatric very-high-risk first-relapse B-cell acute lymphoblastic leukaemia.1 The data support a less toxic bridge to haematopoietic stem cell transplantation (HSCT), but the response denominators support a more specific clinical interpretation: inotuzumab ozogamicin is best viewed as cycle-1 molecular triage, not prolonged reinduction or a replacement for UK ALLR3 chemotherapy. Because ITCC-059 was a single-arm study and its statistical design was modified from 43 to 31 patients while increasing the alpha-error to 10%, comparative claims should be reframed as response-adapted sequencing. Wed, 09 Sep 2026 22:30:04 +0000
[Correspondence] Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia – Authors' reply We appreciate discussing the ITCC-059 results in response to Xiaogang Hao and colleagues. Wed, 09 Sep 2026 22:30:01 +0000
[In Focus] From approval to practice: are clinicians and health systems ready for gene therapy in sickle cell disease? Once a scientist's dream, gene therapy for sickle cell disease has now entered clinical practice. Autologous gene-based therapies offer a potential curative option for a disease that affects approximately 7·7 million people worldwide and remains associated with substantial morbidity, premature mortality, and entrenched health inequities. Regulatory approval, however, represents only the first step in a much longer translational pathway. Experience from other high-cost innovations suggests that without concurrent investment in implementation, workforce preparation, and financing, access could remain uneven or delayed. Thu, 01 Oct 2026 00:00:00 -0700
[In Focus] Vernon Louw: expanding access to clinical haematology in Africa Vernon Louw was not that interested in haematology at first. As an undergraduate he had found the teaching “very laboratory based” and he “struggled to connect it with the patients behind the results”. This sentiment changed when he began treating patients with haematological malignancies as a registrar in internal medicine. “I came to appreciate that haematology combines complex diagnostic reasoning, laboratory science, and long-term relationships with patients in a particularly compelling way”, he recalled. Thu, 01 Oct 2026 00:00:00 -0700
[In Focus] Integrating sexual health into sickle cell disease care Sexual health is a fundamental component of overall wellbeing, yet it remains one of the least addressed dimensions of care for people living with sickle cell disease. At the ASCAT 2025 meeting in London, UK, ERN-EuroBloodNet and RADeep registry convened a 3-day patient educational workshop dedicated to this topic. The sessions brought together 27 people living with sickle cell disease and a multidisciplinary team comprising one obstetrician, one internist, two haematologists, and two psychologists, creating an intergenerational and intercultural space, with 13 countries represented to exchange perspectives. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2) To our knowledge, this is first clinical study of a Bruton tyrosine kinase inhibitor, rilzabrutinib, in warm autoimmune haemolytic anaemia. Rilzabrutinib showed robust overall and durable haemoglobin response and favourable safety in patients with previously treated warm autoimmune haemolytic anaemia. Rilzabrutinib has the potential to treat the underlying pathophysiology of warm autoimmune haemolytic anaemia through multi-immune modulation, induce a robust and sustained haemoglobin response, and provides an opportunity to decrease or stop corticosteroid use. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial Rilzabrutinib showed continued, stable, and sometimes improved platelet responses, including in patients who were initially non-responsive in the double-blind trial. Additionally, rilzabrutinib improved several disease aspects, including physical fatigue and bleeding, supporting its multi-immune modulation mechanism in immune thrombocytopenia, and had a favourable safety profile. The long-term extension period of LUNA3 will further characterise the long-term efficacy and safety of rilzabrutinib in patients with difficult-to-treat immune thrombocytopenia, and the ongoing LUNA4 trial (NCT07007962) will determine the efficacy of rilzabrutinib in earlier-line treatment and its potential to achieve sustained treatment-free response. Thu, 17 Sep 2026 22:30:01 +0000
[Articles] Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial Felzartamab plus lenalidomide–dexamethasone significantly prolonged progression-free survival compared with lenalidomide–dexamethasone alone, supporting felzartamab plus lenalidomide–dexamethasone as a potential new treatment option for Chinese patients with relapsed or refractory multiple myeloma. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial Topical ruxolitinib showed significant clinical activity and favourable harms profile in active cutaneous cGVHD. Ruxolitinib cream could represent a steroid-sparing, skin-directed alternative or second-line therapy, expanding treatment options for patients with cutaneous cGVHD. Wed, 16 Sep 2026 22:30:02 +0000
[Review] High time for risk-adapted treatment in mantle cell lymphoma Mantle cell lymphoma has multiple treatment options, yet the disease is difficult to cure. Relapses are common, treatments can cause severe side-effects, and current recommendations are still largely based on age rather than biology. Although suitability for intensive treatment was previously the decisive parameter, increasing knowledge on the biology of mantle cell lymphoma and less toxic targeted therapies has made non-risk adapted treatments outdated. TP53 mutations or deletions, blastoid histology, and a high Ki-67 proliferation index consistently identify patients at high risk of relapse. Wed, 02 Sep 2026 22:30:01 +0000
[Review] At the heart of unmet need: TP53 myeloid neoplasms TP53 myeloid neoplasms are being increasingly encountered in clinical practice and have been recognised in 2022, as a unique entity in the setting of functional loss of the two copies of the gene. The classification of myeloid neoplasm based on presence of biallelic (multi-hit) TP53 should precede morphological classification. The identification of biallelic (multi-hit) inactivation continues to evolve and is a matter of great debate balancing definitive biallelic identification via assays, pathology classifications, and clinical applicability. Thu, 01 Oct 2026 00:00:00 -0700
[Personal View] Redefining plasma cell leukaemia Plasma cell leukaemia is an aggressive plasma cell malignancy characterised by the presence of a high percentage of circulating clonal plasma cells on conventional peripheral blood smear examination. We argue that plasma cell leukaemia must no longer be considered as a separate disease entity but as a type of high-risk multiple myeloma. With the adoption of more strict criteria for defining high-risk multiple myeloma and the relaxation of criteria in defining plasma cell leukaemia, the clinical implications of the terms have converged. Fri, 21 Aug 2026 22:30:01 +0000
|
VEN-IBR in older and TP53-mt MCL: have sympathy for SYMPATICO
Volume 148, Issue 12 September 17 2026 PKMYT1 as an Achilles’ heel in TP53-deficient myeloma Volume 148, Issue 12 September 17 2026 Redirecting traffic via m6A Volume 148, Issue 12 September 17 2026 RAS seals fate in AML besieged by FLT3 and BCL2 inhibitors Volume 148, Issue 12 September 17 2026 Could a psoriasis treatment be effective for JMML? Volume 148, Issue 12 September 17 2026 A novel Band 3–BLVR axis in red blood cells Volume 148, Issue 12 September 17 2026 Decentralized clinical trials in hematology: the promise and the peril For many challenging hematologic disorders, clinical trials provide the best option for management of a patient’s condition. However, access is a barrier, especially for those living away from major centers, which typically are the hosts for many major trials. Removing the distance barrier would accelerate accrual and completion, while broadening the enrolled patient population to better reflect the true pool of unmet need. Petrone, Uy, and Bolton discuss the principles and practicalities of decentralized clinical trials in this Perspective article, providing their experience in an interventional trial to illustrate how the time is right for greater emphasis on this more patient-centric approach.
Volume 148, Issue 12 September 17 2026 How I treat chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists It is a common occurrence. Moderate and severe thrombocytopenias are regularly induced by cytotoxic chemotherapy regimens in common use across hematology and oncology. Most patients do not need prophylaxis or treatment, but some do. How to identify these patients and how to manage them in an evidence-based way are tackled by Al-Samkari and Soff. Using 4 cases as illustrations, they provide practical, evidence-based advice on the use of thrombopoietin receptor agonists in challenging settings.
Volume 148, Issue 12 September 17 2026 First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations In relapsed mantle cell lymphoma (MCL), the combination of ibrutinib and venetoclax improves progression-free survival, but not overall survival, when compared with ibrutinib monotherapy, with the greatest benefits in patients with adverse genetic features. In this month’s CME article, Wang and colleagues report single-arm trial data for first-line use of this regimen in patients at least 65 years old or with TP53 mutations, revealing high and durable complete responses in non-TP53-mutant MCL and a 55% complete response rate but less durability in TP53-mutant MCL. While impressive compared to historical data with chemotherapy-based regimens, the data indicate that this regimen is not the solution for TP53-mutant MCL and novel approaches are urgently required.
Volume 148, Issue 12 September 17 2026 PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma Deletion of chromosome 17p [del(17p)]/TP53-mutant multiple myeloma (MM) remains a significant unmet clinical need despite the rapid recent advances in therapy. Using a knockout screen and analyses of publicly available genomic and transcriptomic data, Schavgoulidze and colleagues identified PKMYT1, a member of the Wee family of kinases known to regulate mitotic entry and protect genome integrity, as a vulnerability for TP53-deficient MM. They demonstrate that it is pharmacologically tractable, with inhibition being highly active against patient-derived xenografts and in immunocompetent murine models, creating key evidence supporting clinical study of this targeted approach.
Volume 148, Issue 12 September 17 2026 The N6-methyladenosine reader IGF2BP2 in T-cell lymphoma Volume 148, Issue 12 September 17 2026 Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy FMS-like tyrosine kinase 3 (FLT3) mutations, typically internal tandem duplications, occur in approximately one-quarter of all acute myeloid leukemias (AMLs), and outcomes have improved significantly with the addition of FLT3 inhibitors. In relapsed disease, the combination of the FLT3 inhibitor gilteritinib and venetoclax is highly active, but recurrence is inevitable. Exploiting serial samples and single-cell techniques, Kennedy and colleagues report the clonal and nonclonal mechanisms of resistance leading to these relapses. Under this therapeutic pressure, RAS-pathway activation is favored, and downstream inhibitors of this pathway may have a future role in controlling or preventing recurrent leukemia.
Volume 148, Issue 12 September 17 2026 Therapeutic targeting of IL-17A–driven PTGS2/NLRP3 inflammasome activation in juvenile myelomonocytic leukemia Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative neoplasm that occurs exclusively in young children. It is underpinned in >90% of cases by germ line or somatic mutations in RAS-pathway genes, but elevated inflammatory signaling is a hallmark. Pasupuleti et al explored the basis for this, pinpointing interleukin-17A (IL-17A) as promoting an immunosuppressive microenvironment conducive to treatment-refractory disease. They show that genetic or pharmacological disruption of IL-17A in murine models reverses much of the pathology of JMML, suggesting that clinical trials of the antipsoriasis therapy secukinumab are a logical next step.
Volume 148, Issue 12 September 17 2026 The red blood cell proteome and interactome identify a Band 3–BLVRB axis regulating hypoxic metabolic adaptation Red blood cells (RBCs) must be deformable, and this is enabled by the nature of their cell membrane, a lipid bilayer traversed by integral membrane proteins, such as Band 3. Using proteomics and functional experiments, Issaian et al reveal biliverdin reductase B (BLVRB) as a new Band 3 partner, showing that it translocates to, or dissociates from, the RBC membrane as oxygenation conditions change. Their data demonstrate a novel functional axis involving BLVRB–Band 3 in metabolic remodeling of RBCs in response to exercise and to deoxygenation.
Volume 148, Issue 12 September 17 2026 Liu Y, Chen Q, Jeong H-W, et al. Dopamine signaling regulates hematopoietic stem and progenitor cell function. Blood. 2021;138(21):2051-2065. Volume 148, Issue 12 September 17 2026 Sasca D, Hähnel PS, Szybinski J, et al. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood. 2014;124(1):121-133. Volume 148, Issue 12 September 17 2026 First-line ibrutinib plus venetoclax for MCL Volume 148, Issue 12 September 17 2026 |
Soluble Transferrin Receptor and the sTfR/Log Ferritin Index May Not Be Better Than Ferritin Alone for Diagnosis of Anemia of Chronic Disease and Iron Deficiency Anemia
Wed, 30 Sep 2026 18:15:08 -0700 Response to “Undetectable Hydroxyurea in an Untimed Blood Sample Does Not Establish Nonadherence” Tue, 29 Sep 2026 21:14:26 -0700 Overall Survival Benefit and Long‐Term Safety of Romiplostim in Persistent Chemotherapy‐Induced Thrombocytopenia Mon, 28 Sep 2026 05:38:50 -0700 What Does “Non‐Transfusion‐Dependent” Measure in Clinical Trials? Fri, 25 Sep 2026 20:04:55 -0700 Ferritin Alone Is Not Sufficient to Diagnose Iron Deficiency in Patients With Anemia due to Chronic Disease Thu, 24 Sep 2026 17:50:40 -0700 Immune Effector Cell Therapies for Immune Thrombocytopenia Concurrent With Hematologic Malignancy Wed, 23 Sep 2026 05:10:34 -0700 Cerebral Small Vessel Disease in Immune‐Mediated Thrombotic Thrombocytopenic Purpura Patients During the Acute Phase and Disease Remission Tue, 22 Sep 2026 21:17:12 -0700 Superficial Vein Thrombosis During Pregnancy and Postpartum—Findings From the French Multicenter Cohort “HEMOTHEPP” Study Sun, 20 Sep 2026 23:12:44 -0700 Real‐World Experience of Mitapivat in Pyruvate Kinase Deficiency Fri, 18 Sep 2026 05:50:14 -0700 Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients Thu, 17 Sep 2026 22:17:10 -0700 Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk‐Stratification, and Treatment Tue, 15 Sep 2026 00:00:00 -0700 Could Mixed CAR T‐Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel? Sun, 13 Sep 2026 19:05:33 -0700 Basophilic Stippling Unmasks Pyrimidine 5′‐Nucleotidase Deficiency in a G6PD‐Deficient Patient Thu, 10 Sep 2026 02:14:34 -0700 Splenic Tropism and Spleen‐Modulated Systemic Inflammation in Acute Plasmodium vivax Malaria Thu, 10 Sep 2026 00:00:00 -0700 The Presence and Percentage of Circulating Nucleated Red Blood Cells Reveal Distinct Characteristics in Adults With Sickle Cell Disease Wed, 09 Sep 2026 21:50:52 -0700 Noninvasive Diagnosis of Splenosis Using Tc‐99m Heat‐Denatured Red Blood Cell Scintigraphy Wed, 09 Sep 2026 21:32:12 -0700 Anticoagulant Therapy and Bleeding‐Related Hospitalizations in Patients With Cancer: A National Cohort Study Mon, 07 Sep 2026 20:59:50 -0700 Obesity‐Related Inflammation Masks Iron Deficiency in US Women Sun, 06 Sep 2026 21:37:12 -0700 Clonally Related Chronic Lymphocytic Leukemia and Malignant Histiocytic Neoplasm (Histiocytic Sarcoma With Overlapping Langerhans Cell Phenotype): Divergent Evolution From a Shared Cell‐Of‐Origin Sat, 05 Sep 2026 01:59:39 -0700 Robustness of Hemophagocytic Lymphohistiocytosis Risk Estimates in CAR T‐Cell Therapy Thu, 03 Sep 2026 22:10:33 -0700 Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma Thu, 03 Sep 2026 06:11:42 -0700 |
|
|
| |||
|
Stretching a doublet into a triplet for FLT3 AML September 8 2026 - Volume 10, Issue 17 Shuffling the JAKs: playing a new card in chronic GVHD September 8 2026 - Volume 10, Issue 17 When endurance running leads to functional iron deficiency September 8 2026 - Volume 10, Issue 17 Doing more with less in hemophilia B gene therapy September 8 2026 - Volume 10, Issue 17 CAR T before the storm: early consolidation in B-ALL September 8 2026 - Volume 10, Issue 17 American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemia September 8 2026 - Volume 10, Issue 17 Myelodysplasia in VEXAS syndrome September 8 2026 - Volume 10, Issue 17 Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML September 8 2026 - Volume 10, Issue 17 Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study September 8 2026 - Volume 10, Issue 17 A comprehensive multicenter study assessing the impact of abelacimab, asundexian, and milvexian on coagulation assays September 8 2026 - Volume 10, Issue 17 Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma September 8 2026 - Volume 10, Issue 17 EuroNet-PHL-LP1: complete resection or low-dose chemotherapy for pediatric low-risk nodular lymphocyte–predominant Hodgkin lymphoma September 8 2026 - Volume 10, Issue 17 Outcomes of adolescents and young adults with AML treated on pediatric vs adult protocols September 8 2026 - Volume 10, Issue 17 A machine learning–derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL September 8 2026 - Volume 10, Issue 17 Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL September 8 2026 - Volume 10, Issue 17 Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study September 8 2026 - Volume 10, Issue 17 Increased gene therapy efficacy through the use of extended half-life clotting factors September 8 2026 - Volume 10, Issue 17 Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT September 8 2026 - Volume 10, Issue 17 CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission September 8 2026 - Volume 10, Issue 17 Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL September 8 2026 - Volume 10, Issue 17 Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia September 8 2026 - Volume 10, Issue 17 KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasm September 8 2026 - Volume 10, Issue 17 Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement September 8 2026 - Volume 10, Issue 17 Maintenance therapy and improved relapse-free survival in patients with monoclonal gammopathy of renal significance September 8 2026 - Volume 10, Issue 17 Long-distance trail running induces functional iron deficiency driven by inflammation September 8 2026 - Volume 10, Issue 17 Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias September 8 2026 - Volume 10, Issue 17 Cardiovascular risk scores estimate arterial thrombotic risk in aging adults with hemophilia in the ADVANCE Japan cohort September 8 2026 - Volume 10, Issue 17 Mutational profiling links biologically relevant variants to multisystemic Rosai-Dorfman disease September 8 2026 - Volume 10, Issue 17 TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma September 8 2026 - Volume 10, Issue 17 Secondary anticoagulation prophylaxis for children with antiphospholipid syndrome: a systematic review and meta-analysis September 8 2026 - Volume 10, Issue 17 Class 3 MAP2K1 mutations associate with relapse and multiple treatment lines in multisystem Langerhans cell histiocytosis September 8 2026 - Volume 10, Issue 17 Minimal residual disease by high-throughput sequencing in standard risk–favorable pediatric B-lymphoblastic leukemia September 8 2026 - Volume 10, Issue 17 Complementary targeted constructs factor XI/XIa inhibition September 8 2026 - Volume 10, Issue 17 E-lesion or stage IV disease? An ongoing unsettled issue in pediatric Hodgkin lymphoma September 8 2026 - Volume 10, Issue 17 Revisiting KIR restriction and CD94 expression in diagnostic criteria for NK–large granular lymphocytic leukemia September 8 2026 - Volume 10, Issue 17 Immunophenotyping challenges in the diagnosis of NK-LGLL September 8 2026 - Volume 10, Issue 17 Diagnosis of NK–large granular lymphocytic leukemia September 8 2026 - Volume 10, Issue 17 Heestermans R, Olsen C, Ameli S, et al. Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma. Blood Adv. 2025;9(16):4306-4310. September 8 2026 - Volume 10, Issue 17 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Giredestrant plus Everolimus in Advanced Breast Cancer
New England Journal of Medicine, Volume 395, Issue 13, Page 1285-1298, October 1, 2026.
Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults New England Journal of Medicine, Volume 395, Issue 13, Page 1259-1272, October 1, 2026.
Andes Virus — A Clinical Review New England Journal of Medicine, Volume 395, Issue 13, Page 1310-1317, October 1, 2026.
Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia New England Journal of Medicine, Volume 395, Issue 13, Page 1345-1347, October 1, 2026.
Bilateral Pacing Neuromuscular Prosthesis for Laryngeal Paralysis New England Journal of Medicine, Volume 395, Issue 13, Page 1340-1342, October 1, 2026.
Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310 New England Journal of Medicine, Volume 395, Issue 13, Page 1343-1345, October 1, 2026.
Statins in Older Adults — Evidence at Last New England Journal of Medicine, Volume 395, Issue 13, Page 1327-1328, October 1, 2026.
An Echo Unheard New England Journal of Medicine, Volume 395, Issue 13, Page 1319-1325, October 1, 2026.
Thyroglossal Duct Cyst New England Journal of Medicine, Volume 395, Issue 13, Page 1318-1318, October 1, 2026.
Tobacco-Cessation Treatment for Global Impact New England Journal of Medicine, Volume 395, Issue 13, October 1, 2026.
Vaping for Crypto — Smart Devices, Risky Business New England Journal of Medicine, Volume 395, Issue 13, Page 1252-1253, October 1, 2026.
Opioid-Settlement Funds — Lessons from Tobacco New England Journal of Medicine, Volume 395, Issue 13, Page 1249-1251, October 1, 2026.
Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty New England Journal of Medicine, Ahead of Print.
Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism New England Journal of Medicine, Ahead of Print.
Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis New England Journal of Medicine, Ahead of Print.
Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation New England Journal of Medicine, Ahead of Print.
Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension New England Journal of Medicine, Ahead of Print.
Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain New England Journal of Medicine, Ahead of Print.
Prevalence of Silent Atherosclerosis across Adult Life New England Journal of Medicine, Ahead of Print.
Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event New England Journal of Medicine, Ahead of Print.
Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI New England Journal of Medicine, Ahead of Print.
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis New England Journal of Medicine, Ahead of Print.
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes New England Journal of Medicine, Ahead of Print.
IARC Perspective on Lung Cancer Screening New England Journal of Medicine, Ahead of Print.
Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609. New England Journal of Medicine, Ahead of Print.
|
|
|
| |||
|
|
A Penny for Your Thoughts October 2026: 69(10):2399-2401 Ventral Mesh Rectopexy and Rectal Cancer: An Underrecognized Concern October 2026: 69(10):2402-2403 Artificial Intelligence for Colorectal Surgeons—Part II: Research Applications, Challenges in Adoption, and Practical Resources October 2026: 69(10):2404-2412 What Every Colorectal Surgeon Should Know About Private Equity in Ambulatory Practices: Structure, Practice Models, and Implications for Physicians October 2026: 69(10):2413-2417 Compliance With the American Society of Colon and Rectal Surgeons Preoperative Checklist in Rectal Cancer Care in Ghana: Gaps and Opportunities for Improvement—A Cross-Sectional Study October 2026: 69(10):2418-2424 Management and Survivorship Considerations in Early-Onset Rectal Cancer October 2026: 69(10):2425-2428 Expert Commentary on Management and Survivorship Considerations in Early-Onset Rectal Cancer October 2026: 69(10):2429-2430 The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Left-Sided Colonic Diverticulitis October 2026: 69(10):2431-2450 Lymph Node Harvest and Prognosis in Stage II and III Rectal Cancer in the Era of Total Neoadjuvant Therapy October 2026: 69(10):2451-2461 Outcomes and Molecular Correlates of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases October 2026: 69(10):2462-2472 Three-Year Follow-up of the Randomized Trial Comparing Open Versus Laparoscopic Surgery for Primary Tumor Resection in Patients With Noncurable Stage IV Colon Cancer (JCOG1107) October 2026: 69(10):2473-2483 Five-Year Follow-up of the Double-Blinded Randomized Controlled Trial Comparing Laser Hemorrhoidoplasty With Sutured Mucopexy and Excisional Hemorrhoidectomy October 2026: 69(10):2484-2491 Patterns and Outcomes of Elective Versus Nonelective Rectal Prolapse Repair: An American College of Surgeons National Quality Surgical Improvement Program Analysis October 2026: 69(10):2492-2499 Short- and Long-term Outcomes of 3-Row Vs 2-Row Circular Staplers for Low Colorectal Anastomosis After Total Mesorectal Excision: A Single-Center, Randomized, Single-Blind, Phase III Trial (THREESTAPLER Study) October 2026: 69(10):2500-2510 Clinical and Physiological Characterization of Neurogenic Bowel Dysfunction in Motor-Incomplete Spinal Cord Injury October 2026: 69(10):2511-2520 Computer Vision Approach to Triaging Patient-Submitted Photos of Intestinal Ostomies October 2026: 69(10):2521-2530 Selected Abstracts October 2026: 69(10):2531-2534 Single Incision Plus One Robot-Assisted Surgery for Right-Sided Colon Cancer October 2026: 69(10):2535-2535 Video Demonstration of Single-Port Robotic Transanal Total Mesorectal Excision Using Newly Developed Surgical Robot System October 2026: 69(10):2536-2537 Mastering the Planes: Laparoscopic Left Hemicolectomy With Complete Mesocolic Excision October 2026: 69(10):2538-2539 |
||
|
| |||
|
FDA Approves First-Line Pirtobrutinib for CLL/SLL
On October 2, the U.S. Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion. Friday, October 2, 2026 5:15 PM Lung Cancer: AI Model May Predict Pneumonitis Risk From Immunotherapy A deep learning foundation model was able to predict pneumonitis risk from immune checkpoint inhibition therapy in patients with non–small cell lung cancer (NSCLC) based on baseline computed tomography (CT) scans, according to findings published in the Journal for ImmunoTherapy of Cancer. Friday, October 2, 2026 1:30 PM FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer Friday, September 18, 2026 3:13 PM Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality Cancer death rates fell for both men and women from 2019 to 2023, continuing a downward trend that has lasted more than 20 years, according to the 2026 Annual Report to the Nation on the Status of Cancer, published by Henley et al in the journal Cancer. The continued decline in cancer deaths is... Friday, October 2, 2026 11:15 AM Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence? Among patients with ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery, negative surgical margins narrower than 2 mm were not associated with a significantly higher risk of ipsilateral recurrence compared with margins of at least 2 mm—except among patients younger than age... Pembrolizumab/Olaparib Strategy in BRCA-Nonmutated Advanced Ovarian Cancer A pembrolizumab/olaparib strategy significantly improved progression-free survival in patients with newly diagnosed BRCA-nonmutated advanced epithelial ovarian cancer, although overall survival was not improved. Ignace Vergote, MD, PhD, and colleagues reported results from the phase III... Cleveland Clinic London Appoints Oncology Vice Chief Cleveland Clinic London has appointed Heather Shaw, MD, FRCP, as Oncology Vice Chief, reinforcing the organization’s commitment to expanding access to advanced, multidisciplinary cancer care in the United Kingdom. Thursday, October 1, 2026 10:50 AM NCCN Models How to Tailor Cancer Care for Different Regions During 2026 World Cancer Congress The biennial World Cancer Congress, organized by the Union for International Cancer Control (UICC), is the leading international conference on cancer control, bringing together researchers, clinicians, advocates, policymakers, and people with lived experience from more than 120 countries. Two... Thursday, October 1, 2026 10:00 AM IARC Panel Provides International Determination on Lung Cancer Screening's Benefits and Harms The International Agency for Research on Cancer (IARC) has published a comprehensive international evaluation on lung cancer screening in The New England Journal of Medicine. Thursday, October 1, 2026 2:30 PM Multicancer Early Detection Screening Does Not Reduce Overall Late-Stage Cancer Diagnosis Can Long Distance Running Be a Risk Factor for Early-Onset Colorectal Cancer? Colorectal cancer, once thought of as mainly a disease of the aging, is rising in younger adults by nearly 3% per year and is now a leading cause of cancer-related death among individuals under the age of 50.1 According to the American Cancer Society, in 2026, nearly 159,000 individuals will be... FDA Launches Effort to Expand Scientific Expertise, Consumer Voice to Advisory Committees The U.S. Food and Drug Administration (FDA) recently announced a broad, nationwide recruitment effort to expand the range of qualified voices and perspectives on its advisory committees. The FDA is publishing two Federal Register notices: one seeking qualified scientific, technical, and... Thursday, October 1, 2026 12:46 PM Depression Increases Cancer-Specific Mortality Risks in Common Cancers Depression in patients with cancer may be associated with a higher mortality risk, according to findings from a large SEER-Medicare analysis presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 195). The analysis found that psychotherapy soon after... Wednesday, September 30, 2026 12:30 PM Real-World Data Indicate Lower Adherence Rates for Breast Cancer Endocrine Therapy When Radiation Therapy Is Omitted Many patients with early-stage breast cancer do not consistently maintain the long-term hormone therapy prescribed after lumpectomy, a large U.S. insurance claims analysis indicates. Findings provide important real-world context for treatment approaches that consider omitting radiation therapy,... Wednesday, September 30, 2026 11:01 AM SYMPRO-Lung: Could Weekly PRO Symptom Monitoring Improve Survival Outcomes in Any-Stage Lung Cancer? According to results from a post hoc analysis of the SYMPRO-Lung trial published in The Lancet Oncology, weekly patient-reported outcome (PRO) symptom monitoring may be associated with improved long-term overall survival among patients across all stages of lung cancer. Hassing et al reported that... Mindfulness and Tai Chi May Improve Symptoms After Cancer Treatment Mindfulness-based cancer recovery and Tai Chi/Qigong were associated with improvements in fatigue and pain interference among distressed individuals who had completed cancer treatment, with Tai Chi/Qigong also improving sleep quality, according to findings from the Mindfulness and Tai Chi for... Cleveland Clinic to Host Second Annual AI Summit for Health-Care Professionals AI is one of the most transformative technological advancements of our time, poised to revolutionize every aspect of our lives, including health care. On August 28, 2026, Cleveland Clinic in collaboration with the College of Healthcare Information Management Executives (CHIME), will host the Second ... Thursday, August 20, 2026 10:30 AM Cleveland Clinic President Discusses Friday’s AI Summit for Health-Care Professionals Artificial intelligence (AI) is one of the most transformative technological advancements of our time, poised to revolutionize every aspect of our lives, including health care. Wednesday, August 26, 2026 3:41 PM AI’s Evolving Role in Clinical Care Enterprise-Wide Artificial intelligence could reshape health care by reducing administrative work, helping physicians identify and manage disease, and extending care beyond traditional clinical settings—potentially allowing caregivers to focus more on patient care and human interaction, according to Cleveland... Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer Five-treatment stereotactic body radiation therapy (SBRT) may offer an effective alternative to surgery for patients with localized prostate cancer. In long-term follow-up findings from the phase III PACE-A trial presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting ( Tuesday, September 29, 2026 12:30 PM Cancer Statistics 2026: What Every Medical Oncologist Should Know Cancer remains a dominant driver of morbidity and mortality globally and in the United States and continues to impose a substantial and evolving public health burden. Although age-adjusted cancer mortality has declined steadily for more than 3 decades, demographic aging and population growth have... Short-Course SBRT Better Preserves Physical Function Before Pancreatic Cancer Surgery Patients preparing for pancreatic cancer surgery maintained better physical function and experienced less fatigue with 5 treatments of stereotactic body radiation therapy (SBRT) than with 28 treatments of conventional radiation therapy given with chemotherapy, according to findings of a randomized... Tuesday, September 29, 2026 10:51 AM Ultra–Low-Dose Radiation Therapy May Relieve Bone Pain From Multiple Myeloma A short course of ultra–low-dose radiation therapy relieved painful bone lesions from multiple myeloma for patients in a multi-institutional phase II clinical trial. The findings suggest that a lower-intensity approach could help ease patients’ pain without interrupting other treatment and with few ... Tuesday, September 29, 2026 11:31 AM New Prognostic Model May Improve Risk Classification in Metastatic Clear Cell RCC A new prognostic model developed for the checkpoint inhibitor era showed better discrimination of survival outcomes in patients with previously untreated metastatic clear cell renal cell carcinoma (RCC) than the widely used International Metastatic RCC Database Consortium (IMDC) model. The... Adding Targeted Immunotherapy to Pembrolizumab in Recurrent or Metastatic HPV16-Positive Head and Neck Squamous Cell Carcinoma Based on the results of the nonrandomized multicenter phase II VERSATILE-002 trial reported in JAMA Oncology, a regimen adding the human papillomavirus type 16 (HPV16)-targeted immunotherapy PDS0101 to pembrolizumab demonstrated antitumor activity in immune checkpoint inhibitor–naive patients with... SRS Is a "Reasonable Option" for Patients With SCLC and Brain Metastases Stereotactic radiosurgery demonstrated a prolonged overall survival compared with hippocampal-avoidant whole-brain radiotherapy with memantine in patients with small cell lung cancer (SCLC) and brain metastases, according to phase III study findings presented at the 2026 American Society for... Monday, September 28, 2026 12:30 PM |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
Benefit with post-consolidation blinatumomab in newly diagnosed high-risk B-ALL
Benefit with post-consolidation blinatumomab in newly diagnosed high-risk B-ALL Thu, 01 Oct 2026 00:00:00 -0700 Optimizing the delivery of radiotherapy with artificial intelligence Radiation oncology involves complex, data-intensive clinical workflows, which makes this medical specialty an ideal setting for leveraging the unique capabilities of artificial intelligence (AI). The authors of this Review present examples of successful AI applications in radiation oncology, present the current challenges for successful clinical implementation of these applications and discuss broader implications, such as the need to ensure safe and optimal use of AI in order to improve patient outcomes. Thu, 24 Sep 2026 00:00:00 -0700 Tambotatug pelitecan — a potential new second-line treatment option for SCLC Tambotatug pelitecan — a potential new second-line treatment option for SCLC Tue, 22 Sep 2026 00:00:00 -0700 Understanding and targeting the tumour matrisome The extracellular matrix (ECM) has a role in all aspects of cancer progression and thus provides a rich source of potential tumour biomarkers and therapeutic targets. Nonetheless, early efforts at clinical translation have failed to provide ECM-specific clinical tools or therapies. In this Review, the authors describe novel technologies and how these are being leveraged to better inform our understanding of the role of the ECM in cancer development and progression as well as how this new knowledge and capabilities might lead to novel biomarkers and/or ECM-targeting therapies. Mon, 21 Sep 2026 00:00:00 -0700 Publisher Correction: Antibody–drug conjugates in gynaecological cancers: opportunities and challenges Publisher Correction: Antibody–drug conjugates in gynaecological cancers: opportunities and challenges Thu, 17 Sep 2026 00:00:00 -0700 Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next? A new chimeric antigen receptor (CAR) T cell product consists of autologous T cells expressing an affinity-tuned glypican 3-targeted CAR and armoured to secrete a dominant-negative TGFβ receptor II. This cell product was tested in 36 patients with hepatocellular carcinoma and, although the initial efficacy results were promising, antigen loss and limited progression-free survival remain concerns. Here we discuss what else is needed to bring CAR T cells for solid tumours into the clinic. Thu, 17 Sep 2026 00:00:00 -0700 Preliminary efficacy with daraxonrasib demonstrated in RAS-mutant NSCLC Preliminary efficacy with daraxonrasib demonstrated in RAS-mutant NSCLC Wed, 16 Sep 2026 00:00:00 -0700 Publisher Correction: Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology Publisher Correction: Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology Fri, 11 Sep 2026 00:00:00 -0700 |
|
|
| |||
|
Prognostic significance of DNA damage response-related markers in esophageal squamous cell carcinoma using machine learning approaches
Vol 17, No 4 (August 31, 2026): The association between coffee consumption and esophageal cancer risk: a systematic review and meta-analysis of current observational evidence Vol 17, No 4 (August 31, 2026): FANCI promotes esophageal squamous cell carcinoma progression and cell cycle regulation and interacts with FANCD2 Vol 17, No 4 (August 31, 2026): Human epidermal growth factor receptor 2 expression loss after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma: a retrospective study Vol 17, No 4 (August 31, 2026): Efficacy and safety of sintilimab-based neoadjuvant regimens in patients with resectable gastric or gastroesophageal junction adenocarcinoma: a single-arm systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Prediction-model development and temporal validation for six-month cancer-specific mortality in de novo metastatic gastroesophageal junction adenocarcinoma: a SEER-based study Vol 17, No 4 (August 31, 2026): Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study Vol 17, No 4 (August 31, 2026): Nodal status and advanced clinical stage as determinants of response and survival after induction chemoradiotherapy in esophageal and gastroesophageal junction cancer: a single-centre retrospective cohort study Vol 17, No 4 (August 31, 2026): Screening of molecular biomarkers ASPN and LBH and construction of a prediction nomogram for the progression of esophagogastric junction adenocarcinoma Vol 17, No 4 (August 31, 2026): Non-structural maintenance of chromosome condensin I complex subunit H knockdown suppresses malignant progression of esophageal squamous cell carcinoma via the Wnt/β-catenin signaling pathway Vol 17, No 4 (August 31, 2026): The prognosis of patients with gastrointestinal stromal tumors harboring the KIT exon 11 mutation: a retrospective cohort study Vol 17, No 4 (August 31, 2026): Cuproplasia-associated LOXL2 cooperates with Helicobacter pylori infection to promote gastric cancer progression via the FAK/Src signaling axis Vol 17, No 4 (August 31, 2026): Development and validation of a nomogram for the non-invasive prediction of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma: an 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based study Vol 17, No 4 (August 31, 2026): Non-invasive prediction of occult peritoneal metastasis (OPM) in gastric cancer using logistic regression and random forest integrative models with CT radiomics and clinical parameters: machine learning prediction of gastric OPM Vol 17, No 4 (August 31, 2026): Helicobacter pylori-induced cystathionine-γ-lyase drives redox imbalance and metabolic remodeling in gastric cancer Vol 17, No 4 (August 31, 2026): Development of a postoperative risk scoring tool for elderly patients with early gastric cancer: an exploratory prognostic score derivation study Vol 17, No 4 (August 31, 2026): Increased expression of Ribonucleic acid export 1 (RAE1) gene promotes gastric carcinogenesis and is associated with Hippo signaling pathway Vol 17, No 4 (August 31, 2026): Impact of spatial distribution of M2 macrophages on prognosis and neoadjuvant chemotherapy resistance in gastric cancer Vol 17, No 4 (August 31, 2026): Distinct metastatic patterns and survival outcomes in intestinal- versus diffuse-type gastric cancer: a SEER-based propensity score-matched analysis Vol 17, No 4 (August 31, 2026): Clinical efficacy and safety of apatinib plus S-1 combined with oxaliplatin (SOX) in postoperative stage III gastric cancer patients with high VEGFR-2 expression Vol 17, No 4 (August 31, 2026): A predictive nomogram model for overall survival in obstructive colorectal cancer based on clinical and laboratory indicators Vol 17, No 4 (August 31, 2026): Trajectory identification of high-risk subgroups after colorectal cancer surgery in patients with minimal residual disease: a single-center longitudinal study Vol 17, No 4 (August 31, 2026): Histopathological subtypes independently predict survival in ampullary carcinoma: a contemporary SEER nomogram study Vol 17, No 4 (August 31, 2026): Sphingosine-1-phosphate induces angiogenesis via the activating STAT3 signaling pathway to drive colorectal cancer progression Vol 17, No 4 (August 31, 2026): Artemisinin inhibits colorectal cancer progression via the FAM83A-AS1/HIF-1α axis Vol 17, No 4 (August 31, 2026): Metabolic-cell-death gene trio predicts survival and cuproptosis sensitivity in colorectal cancer Vol 17, No 4 (August 31, 2026): Real-world efficacy and safety of fruquintinib plus PD-1 inhibitors with or without radiotherapy in refractory metastatic colorectal cancer: a single-center retrospective cohort study Vol 17, No 4 (August 31, 2026): Association between metabolic dysfunction-associated steatotic liver disease and risk of early-onset advanced colorectal neoplasia: a systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): MS4A3 as a potential prognostic biomarker for colon cancer: integrated analysis of expression patterns and immune cell infiltration Vol 17, No 4 (August 31, 2026): Radiomic prediction of early progression at 2 years post-treatment in patients with resectable rectal cancer based on rectal tumor and mesentery characteristics: a two-center study Vol 17, No 4 (August 31, 2026): Prognostic significance of lymphovascular invasion in colorectal mucinous adenocarcinoma after curative resection: a nationwide multi-center retrospective cohort study Vol 17, No 4 (August 31, 2026): A study on screening of postoperative chemotherapy beneficial populations in stage II colorectal cancer based on diffusion weighted imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography Vol 17, No 4 (August 31, 2026): Prognostic value of genes associated with metastasis and propionate metabolism in rectal cancer Vol 17, No 4 (August 31, 2026): Global, regional, and national burden of colorectal cancer attributable to modifiable risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Vol 17, No 4 (August 31, 2026): Prognostic impact of mucinous adenocarcinoma after curative surgery for stage I–III colorectal cancer: a large population-based cohort study Vol 17, No 4 (August 31, 2026): Comparative analysis of outcomes and sociodemographic factors in early- and late-onset colorectal cancer hospitalizations Vol 17, No 4 (August 31, 2026): Modifiable risk factors contributing to the rising incidence of early-onset colorectal cancer in the United States over three decades: a Global Burden of Disease analysis Vol 17, No 4 (August 31, 2026): Establishment of a chemoradio-resistance colorectal cancer cell model and its changes in biological behavior Vol 17, No 4 (August 31, 2026): Prediction of histological response by PET-CT after 2 weeks of neoadjuvant chemo-radiotherapy for rectal cancer: a prospective clinical trial Vol 17, No 4 (August 31, 2026): Landscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy Vol 17, No 4 (August 31, 2026): Development and preliminary validation of plasma cell-free DNA methylation-based diagnostic prediction model for colorectal cancer detection Vol 17, No 4 (August 31, 2026): Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial Vol 17, No 4 (August 31, 2026): Application value of dual-phase cone-beam computed tomography during hepatic arteriography in the detection of ≤2 cm hypervascular hepatocellular carcinoma and its feeding arteries Vol 17, No 4 (August 31, 2026): Development and validation of a novel nomogram for predicting long-term survival in gallbladder cancer: a large population-based study using the SEER database Vol 17, No 4 (August 31, 2026): Development and validation of prognostic nomograms for intrahepatic cholangiocarcinoma with concomitant hepatolithiasis after radical resection Vol 17, No 4 (August 31, 2026): Metabolic burden but not metabolic dysfunction-associated steatotic liver disease affects the prognosis of patients with hepatocellular carcinoma after hepatectomy: a retrospective cohort study Vol 17, No 4 (August 31, 2026): Global impact of hepatitis B vaccination on the risk of hepatocellular carcinoma: a systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Immunological characteristics of calmodulin-related genes in hepatocellular carcinoma and their potential for prognostic prediction and diagnostic applications Vol 17, No 4 (August 31, 2026): Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis Vol 17, No 4 (August 31, 2026): Relationships among slow diffusion coefficient and diffusion-derived ‘vessel density’ signal features, Gadoxetate delayed enhancement, tumor size, tumor grading, and patient survival: an exploratory study of mass-forming intrahepatic cholangiocarcinoma Vol 17, No 4 (August 31, 2026): Construction of molecular signatures based on the co-expression network of NECSO-related gene TRPM4 and its prognostic value in hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): Organ-specific response to atezolizumab + bevacizumab combination therapy for unresectable hepatocellular carcinoma with extrahepatic metastases: a retrospective cohort study Vol 17, No 4 (August 31, 2026): A practical nomogram for predicting survival in patients with extrahepatic cholangiocarcinoma: a population-based cohort study Vol 17, No 4 (August 31, 2026): SLC25A45 as a prognostic biomarker promotes malignant progression via mutant p53 in hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): A novel glutamine metabolism-based classification system for characterizing the heterogeneity of hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): A CFH- and SPINT2-based prognostic signature for cholangiocarcinoma Vol 17, No 4 (August 31, 2026): Evolving burden of pancreatic cancer in the Middle East and North Africa Region, 1990–2023: an analysis based on the Global Burden of Disease Study 2023 Vol 17, No 4 (August 31, 2026): Association between preoperative statin use and survival after pylorus-preserving pancreaticoduodenectomy for pancreatic or periampullary cancer: a propensity score-matched cohort study Vol 17, No 4 (August 31, 2026): Development and validation of a nomogram based on three-dimensional quantitative parameters from dual-layer detector spectral computed tomography for predicting treatment response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma Vol 17, No 4 (August 31, 2026): Chronic psychological stress and gastric cancer: bidirectional associations, biological mechanisms, and clinical implications—a narrative review Vol 17, No 4 (August 31, 2026): MNAT1 in gastrointestinal cancers: mechanistic insights and therapeutic strategies—a narrative review Vol 17, No 4 (August 31, 2026): Impacts of neoadjuvant therapy on subsequent surgical difficulty, safety, and outcomes in locally advanced rectal cancer: a narrative review Vol 17, No 4 (August 31, 2026): From clinical insight to trial design: advancing circulating tumor DNA-informed care in pancreatic cancer Vol 17, No 4 (August 31, 2026): Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial Vol 17, No 4 (August 31, 2026): Neuroendocrine tumors of unknown primary: a case report and review of tumors with gastroenteropancreatic features Vol 17, No 4 (August 31, 2026): Diagnostic biopsy-to-treatment interval and risk of recurrence in localized pancreatic ductal adenocarcinoma: every week counts Vol 17, No 4 (August 31, 2026): Non-operative management of rectal adenocarcinoma in a safety-net system: a decade of real-world outcomes outside watch-and-wait eligibility Vol 17, No 4 (August 31, 2026): Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Prognostic role of resting heart rate in patients with colorectal cancer Vol 17, No 4 (August 31, 2026): DNA-dependent protein kinase inhibition as a radiosensitizer in rectal cancer: toxicity must be evaluated in the context of organ preservation Vol 17, No 4 (August 31, 2026): Persistent FGFR pathway dependence: where does tinengotinib fit after FGFR inhibitor therapy in advanced cholangiocarcinoma? Vol 17, No 4 (August 31, 2026): Optimizing hepatocellular carcinoma screening in the era of metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease: time to lower the alpha-fetoprotein threshold Vol 17, No 4 (August 31, 2026): Beyond trastuzumab: redefining first-line HER2-positive gastroesophageal cancer with bispecific HER2 targeting Vol 17, No 4 (August 31, 2026): Identifying actionable targets: predicting imatinib nonadherence in patients with gastrointestinal stromal tumors Vol 17, No 4 (August 31, 2026): Therapeutic drug-monitoring-guided desensitization for severe imatinib-associated rash Vol 17, No 4 (August 31, 2026): Endoscopic ultrasonography ablation for small pancreatic neuroendocrine tumors Vol 17, No 4 (August 31, 2026): Extending the utility of anti-EGFR therapy in metastatic colorectal cancer Vol 17, No 4 (August 31, 2026): Cadonilimab plus chemotherapy in PD-L1-low gastroesophageal cancer: a bispecific opportunity? Vol 17, No 4 (August 31, 2026): Ferroptosis in gastrointestinal stromal tumors Vol 17, No 4 (August 31, 2026): Erratum: Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes Vol 17, No 4 (August 31, 2026): |
|
||
|
| |||
|
Patient-Centered Prescription Opioid Tapering Methods
Annals of Internal Medicine, Volume 179, Issue 9, Page 1221-1231, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy Annals of Internal Medicine, Volume 179, Issue 9, Page 1232-1243, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Glucagon-like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy Annals of Internal Medicine, Volume 179, Issue 9, Page 1244-1253, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis Annals of Internal Medicine, Volume 179, Issue 9, Page 1254-1261, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Real-World Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Mitral Stenosis Annals of Internal Medicine, Volume 179, Issue 9, Page 1262-1270, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Surgery Versus Watchful Waiting for First Metatarsophalangeal Joint Osteoarthritis Annals of Internal Medicine, Volume 179, Issue 9, Page 1271-1279, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Strengthening the Reporting of Observational Studies in Epidemiology Enhanced Prevalence and Incidence Criteria (STROBE EPIC): An Extension of the STROBE Statement Annals of Internal Medicine, Volume 179, Issue 9, Page 1280-1289, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Adult Overweight and Obesity Management: Updates From the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines Annals of Internal Medicine, Volume 179, Issue 9, Page 1296-1311, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Modernizing the Regulatory Framework for Dietary Supplements: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 9, Page 1290-1292, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Public Policy Approaches to Addressing Adult Obesity: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 9, Page 1293-1295, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Dialysis and the Politics of Self-care: The Enduring Effects of Barriers Imposed on Home Dialysis Annals of Internal Medicine, Volume 179, Issue 9, Page 1312-1318, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop Annals of Internal Medicine, Volume 179, Issue 9, Page 1319-1327, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop Annals of Internal Medicine, Volume 179, Issue 9, Page 1328-1337, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Rethinking the Global Transition to LED Lighting: Balancing Energy Efficiency With Human Physiology Annals of Internal Medicine, Volume 179, Issue 9, Page 1338-1340, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 When the Physician Becomes a Candidate Annals of Internal Medicine, Volume 179, Issue 9, Page 1341-1342, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Early Access to GLP-1 Receptor Agonists for Weight Management in Medicare: The GLP-1 Bridge Demonstration Annals of Internal Medicine, Volume 179, Issue 9, Page 1343-1345, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Assessing Front-of-Package Labels: The U.S. Food and Drug Administration’s Proposed Rule in Context Annals of Internal Medicine, Volume 179, Issue 9, Page 1346-1347, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Why Patients Ask the Chatbot First Annals of Internal Medicine, Volume 179, Issue 9, Page 1348-1349, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Securing Patient-Centered Decision Making With Adults With Intellectual and Developmental Disabilities Annals of Internal Medicine, Volume 179, Issue 9, Page 1350-1351, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Beyond “Provider”: Recommendations to Turn Consensus Into Action Annals of Internal Medicine, Volume 179, Issue 9, Page 1352-1353, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Patient-Centered Opioid Tapering: What Is It, and Does It Work? Annals of Internal Medicine, Volume 179, Issue 9, Page 1354-1355, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 A Thousand Letters Annals of Internal Medicine, Volume 179, Issue 9, Page 1356-1357, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 The Cardinal in the Bamboo Annals of Internal Medicine, Volume 179, Issue 9, Page 1358-1359, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 How to Be a Patient Annals of Internal Medicine, Volume 179, Issue 9, Page 1360-1360, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 A Cross-Sectional Assessment of Differences in the U.S. Health Care Workforce by Urbanicity, 2019 to 2023 Annals of Internal Medicine, Volume 179, Issue 9, Page 1361-1363, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Outpatient Antibiotic Prescribing for Uncomplicated Diverticulitis in Veterans Affairs Facilities: A Retrospective Cohort Study Annals of Internal Medicine, Volume 179, Issue 9, Page 1363-1365, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
Kailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic ovarian syndrome.
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’s Humira and UCB’s Bimzelx.
US government launches AI-driven programs to overhaul clinical trials Amid rising industry concerns about U.S. competitiveness with China, the Trump administration is rolling out four ARPA-H initiatives to modernize clinical trial design, site activation, consent and patient data collection.
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years The results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2 study of AMT-130 underestimates disease progression.
J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma Ten patients out of 20 who received Johnson & Johnson and Legend Biotech’s Carvykti remained alive at five years of follow up.
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy body dementia.
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data Kyverna Therapeutics’ miv-cel showed improved mobility and a favorable safety profile at one year in patients with stiff person syndrome, further derisking an upcoming FDA application, William Blair said on Thursday. The biotech plans to file for priority review this year.
Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss After imeroprubart failed to demonstrate sufficient efficacy in lupus during a Phase 2b trial, Immunovant is moving on from the indication and looking to other high Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trial With just over $10 million in cash available to fuel operations through the end of the year, Longeveron is undertaking a strategic review after the failure of a cardiovascular study.
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) Clear Scientific Reports Positive Phase 2 Results for CS-1103, the First Investigational Therapeutic That Removes Fentanyl from the Body āshibio to Present Three Abstracts at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting /UPDATE -- Nektar Therapeutics/ ZYUS Life Sciences Announces Positive Topline Results from Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug in Patients with Advanced Cancer Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI Galimedix Therapeutics presents baseline data from Phase 2 eDREAM trial highlighting patient-tailored microperimetry as a sensitive and precise functional measurement in geographic atrophy studies Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn’s Disease Pfizer’s Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study Faron Announces First Patient Dosed in BLAZE Investigator-Initiated Trial Atsena Presents Positive 18-Month Results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results |
BMS reports liver injury events in lung disease program, with key readout near
Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s program have caused some unease about the drug class.
US government launches AI-driven programs to overhaul clinical trials Amid rising industry concerns about U.S. competitiveness with China, the Trump administration is rolling out four ARPA-H initiatives to modernize clinical trial design, site activation, consent and patient data collection.
Summit snags $2B investment from AstraZeneca, clearing financial overhang The all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights.
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy body dementia.
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data Kyverna Therapeutics’ miv-cel showed improved mobility and a favorable safety profile at one year in patients with stiff person syndrome, further derisking an upcoming FDA application, William Blair said on Thursday. The biotech plans to file for priority review this year.
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study Amgen is awaiting another Phase 3 readout for the investigational Sjögren’s disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an FDA application.
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay transplant.
Ionis-Otsuka offer ‘groundbreaking’ improvement in function and survival for genetic type of ALS Ulefnersen, an RNA-targeted therapy being developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, improved measurements of functional impairment and survival in patients with a rare, genetic ALS subtype in a Phase 3 trial. The partners plan to approach the FDA with the results to determine potential pathways for approval.
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress TriGemX Bio Announces $94M Financing and Initiation of Phase 3 Trials for Elismetrep, A Potential First-in-Class Treatment for Migraine āshibio to Present Three Abstracts at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine Taiho Oncology and Taiho Pharmaceutical Announce Positive Topline Results in Phase 3 AZTOUND Trial Evaluating Oral Azacitidine and Cedazuridine in Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Atsena Presents Positive 18-Month Results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026 New Phase 3b data show Lilly’s EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection Pharmazz, Inc. Receives U.S. FDA IND Clearance to Initiate Phase 3 Clinical Trial of Sovateltide in Traumatic Brain Injury Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis’ Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026 Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder |
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
Kailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic ovarian syndrome.
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’s Humira and UCB’s Bimzelx.
BMS reports liver injury events in lung disease program, with key readout near Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s program have caused some unease about the drug class.
US government launches AI-driven programs to overhaul clinical trials Amid rising industry concerns about U.S. competitiveness with China, the Trump administration is rolling out four ARPA-H initiatives to modernize clinical trial design, site activation, consent and patient data collection.
The race for access: How the FAIR Act could reclaim U.S. biotech leadership In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster.
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.
Biopharma needs to reward scientists’ judgment It’s not enough for organizations to want scientists to think like entrepreneurs. They have to incentivize and reward for that behavior.
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years The results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2 study of AMT-130 underestimates disease progression.
Summit snags $2B investment from AstraZeneca, clearing financial overhang The all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights.
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) Clear Scientific Reports Positive Phase 2 Results for CS-1103, the First Investigational Therapeutic That Removes Fentanyl from the Body TriGemX Bio Announces $94M Financing and Initiation of Phase 3 Trials for Elismetrep, A Potential First-in-Class Treatment for Migraine āshibio to Present Three Abstracts at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration /UPDATE -- Nektar Therapeutics/ ZYUS Life Sciences Announces Positive Topline Results from Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug in Patients with Advanced Cancer ViroMissile Completes First Dose Cohort of Phase I Trial of Intravenously-Dosed IDOV-2; Safety Review Committee Clears Advancement to Next Cohort Montai Therapeutics Doses First Participants in Phase 1 Clinical Trial of MTAI-1025, a Novel Oral NRF2 Agonist for Ulcerative Colitis Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3 Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026 Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI Galimedix Therapeutics presents baseline data from Phase 2 eDREAM trial highlighting patient-tailored microperimetry as a sensitive and precise functional measurement in geographic atrophy studies |
|
|
| |||
|
FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.
Fri, 02 Oct 2026 00:00:02 -0700
FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Thu, 24 Sep 2026 00:00:02 -0700
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.
Wed, 23 Sep 2026 00:00:02 -0700
FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Inluriyo and Verzenio are manufactured by Eli Lilly and Company.
Fri, 18 Sep 2026 00:00:02 -0700
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Wed, 09 Sep 2026 00:00:02 -0700
FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
Fri, 04 Sep 2026 00:00:02 -0700
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Wed, 26 Aug 2026 00:00:02 -0700
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma Tue, 25 Aug 2026 00:00:02 -0700
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 13 Aug 2026 00:00:02 -0700
FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Thu, 06 Aug 2026 00:00:02 -0700
FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
Fri, 31 Jul 2026 00:00:02 -0700
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Wed, 22 Jul 2026 00:00:02 -0700
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
Tue, 14 Jul 2026 00:00:02 -0700
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
Tue, 14 Jul 2026 00:00:02 -0700
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
Fri, 10 Jul 2026 00:00:02 -0700
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications.
Thu, 09 Jul 2026 00:00:02 -0700
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.
Tue, 30 Jun 2026 00:00:02 -0700
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC).
Wed, 24 Jun 2026 00:00:02 -0700
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
Wed, 24 Jun 2026 00:00:02 -0700
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
Fri, 12 Jun 2026 00:00:02 -0700
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Fri, 12 Jun 2026 00:00:02 -0700
FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
Thu, 28 May 2026 00:00:02 -0700
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wed, 27 May 2026 00:00:02 -0700
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Fri, 22 May 2026 00:00:02 -0700
|
Clinical guidelines for treating caries in adults following a minimal intervention policy--evidence and consensus based report.
J Dent. 2012 Feb;40(2):95-105. doi: 10.1016/j.jdent.2011.10.011. Epub 2011 Nov 2. Momoi Y, Hayashi M, Fujitani M, Fukushima M, Imazato S, Kubo S, Nikaido T, Shimizu A, Unemori M, Yamaki C Does Dog Walking Predict Physical Activity Participation: Results From a National Survey. Am J Health Promot. 2016 May;30(5):323-30. doi: 10.1177/0890117116646335. Epub 2016 May 5. Richards EA Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026 Sep 29:S0140-6736(26)01861-1. doi: 10.1016/S0140-6736(26)01861-1. Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A Global, Regional, and National Burden of Heart Failure, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study 2023. JAMA Cardiol. 2026 Sep 30:e264068. doi: 10.1001/jamacardio.2026.4068. GBD 2023 Heart Failure Collaborators; Johnson CO, Abbasi M, Abbasifard M, Abbastabar H, ElHafeez SA, Abdel Razeq NM, Abdelgalil AA, Abdolizadeh A, Abdoun M, Abdrabou M, Abdullahi A, Abebe TB, Abejew AA, Abil OZ, Abiodun O, Aboagye RG, Abohashem S, Aboouf MA, Abouelmagd ME, Abouzid M, Abramov D, Abtahi D, Abuadas FH, Abu-Gharbieh E, Abuhelwa AY, Abushanab D, Adams LC, Addo IY, Adedokun KA, Adegbile OE, Adegoke NA, Adeleke OT, Adeniyi MA, Adesina MA, Adesola RO, Adhikari K, Adisu MA, Adoma PO, Afoakwah C, Afrifa-Yamoah E, Sohail Afzal M, Aghaali M, Agide FD, Agordoh PD, Agostinis Sobrinho C, Agrawal P, Agyemang-Duah W, Ahmad D, Ahmad M, Ahmad S, Ahmad S, Ahmad S, Ahmad W, Ahmadi A, Ahmadi S, Ahmadian S, Ahmadzadeh K, Ahmed A, Ahmed GS, Ahmed MB, Ahmed M, Ahmed S, Ahmed SA, Ajami M, Ajayi AI, Akhigbe RE, Akhtar MN, Al Awaidy ST, Al Bahhawi T, Al Hasan SM, Al Nawayseh MK, Al Thaher Y, Al Zaabi OAM, Al Zoubi MAM, Alahdab F, Al-Ahmad MM, Alalalmeh SO, Alam MK, Alam R, Alanezi F, Alanzi T, Al-Ashwal FY, Alavi R, ALBashtawy MS, Aldabbour B, Al-Dalakta A, Aldawsari KA, Al-Dewik N, Aleidi SM, Alfalki AM, Algammal A, Algethami M, Alhabib K, Alhalaiqa FN, Alhumaydhi FA, Ali I, Ali MD, Ali MU,… Pheochromocytoma Across the Perioperative Course: Current Concepts and Clinical Management. Anesthesiol Res Pract. 2026 Sep 29;2026:4406992. doi: 10.1155/anrp/4406992. eCollection 2026. Mirrakhimov AE, Bashall N Failure of electric shock treatment for rattlesnake envenomation. Ann Emerg Med. 1991 Jun;20(6):659-61. doi: 10.1016/s0196-0644(05)82389-3. Dart RC, Gustafson RA Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026 Sep 29. doi: 10.1056/NEJMoa2604169. Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, Du Y, Makarova N, Giblin K, Schloot NC, Wang Y; TRIUMPH-1 Investigators Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet. 2026 Sep 30:S0140-6736(26)01865-9. doi: 10.1016/S0140-6736(26)01865-9. Klein KR, Wysham C, Tuttle KR, Davies MJ, Cox D, Chen J, Wu WS, Denning M, Liu R, Ludwig L, Meskimen ER Global, regional, and national burden of exposure to chewing tobacco, 1990-2023: a systematic analysis of the Global Burden of Disease Study 2023. Lancet Glob Health. 2027 Jul 20:104043. doi: 10.1016/j.langlo.2026.104043. GBD 2023 Chewing Tobacco Collaborators Histologic Features and Clinical Outcomes of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA. 2026 Sep 30:e2618491. doi: 10.1001/jama.2026.18491. de Avila L, AlNaamani KM, Papatheodoridi M, Petta S, Hagström H, Kim SU, Nakajima A, Crespo J, Castera L, Alkhouri N, Zheng MH, Treeprasertsuk S, Shalimar, Tsochatzis E, Trivikrama SK, Fan JG, Roberts SK, Alswat K, Wong VW, Yilmaz Y, Dunn W, Francque S, Cordie A, Yu ML, Ekstedt M, Goh GB, Oliveira CP, Pessoa MG, Chan WK, Castellanos Fernandez MI, Duseja A, Arab JP, Papatheodoridis G, Sebastiani G, Villela-Nogueira C, D'Ambrosio R, Lampertico P, Holleboom AG, Valsan A, El-Kassas M, Kobayashi T, Kakizaki S, Caussy C, Pearlman B, Pugliese N, Vessby J, Choudhary NS, Kawaguchi T, Russo FP, Gadano A, Diaz LA, Singal AK, Gunn N, Mauricio D, Arrese M, Fracanzani A, Lombardi R, Aghemo A, Alqahtani SA, Stepanova M, Younossi ZM; Global MASLD Study Investigators on behalf of the Global NASH/MASH Council; Ananchuensook P, Balakumaran LK, Lam B, Venu A, Pennisi G, Shang Y, Liu WY, Lee HW, Iruzubieta P, Nadeem R, Cinque F, Zoncapé M, Yang RX, Song SJ, Dunn N, Gadi Z, Yeh ML, Teh KK, Mahadeva S, Fabian LG, Almohsen A, Leite N, Xie C, Friend E, Poca M, Segrestin B, Racila A Teaching may be hazardous to your marriage. Evol Hum Behav. 2000 May 1;21(3):185-190. doi: 10.1016/s1090-5138(00)00026-x. Kanazawa S, Still MC Spatial evolution of a cachexia-promoting microenvironment in pancreatic cancer. Cell. 2026 Sep 29:S0092-8674(26)01081-0. doi: 10.1016/j.cell.2026.09.012. Hu Y, Lv G, Yuan H, Zhou Z, Zhang S, Ye Y, Chen Q, Cai Y, Yang J, Zhang Y, Xu C, Luo W, Bronze MS, Houchen CW, Li YP, Xu J, Zhang Y, Liu M, Li M Playing Tetris decreases drug and other cravings in real world settings. Addict Behav. 2015 Dec;51:165-70. doi: 10.1016/j.addbeh.2015.07.020. Epub 2015 Jul 26. Skorka-Brown J, Andrade J, Whalley B, May J Giredestrant plus Everolimus in Advanced Breast Cancer. N Engl J Med. 2026 Oct 1;395(13):1285-1298. doi: 10.1056/NEJMoa2602457. Mayer EL, Tolaney SM, Martín M, Vidal GA, Moscetti L, Jhaveri KL, Brufsky A, Gradishar WJ, Schneeweiss A, Niikura N, Favret A, Alfie M, Lee KS, Khan S, Feldman MB, Day BM, Lam LH, Darbonne WC, Shah MD, Griffiths KL, DiLallo G, Pérez-Moreno PD, Rugo HS; evERA Breast Cancer Investigators Prion-like transmission of human tau strains in the mouse brain. Nature. 2026 Sep 30. doi: 10.1038/s41586-026-11061-x. Lövestam S, Shimozawa A, Tarutani A, Ohtani R, Masuda-Suzukake M, Hasegawa K, Robinson AC, Saito Y, Murayama S, Yoshida M, Suzuki H, Onaya M, Hasegawa M, Goedert M, Scheres SHW Recurrent Nipple Duct Obstruction in Two Breastfeeding Patients: A Case Report and Discussion of the Underlying Pathophysiology. J Mammary Gland Biol Neoplasia. 2025 Feb 1;30(1):2. doi: 10.1007/s10911-025-09576-6. Sadovnikova A, Greenman S, Young B, Rosen-Carole C The Validity of a Smartphone-Based Method for Acquiring 3D Images of the Face. J Clin Med. 2024 Oct 24;13(21):6362. doi: 10.3390/jcm13216362. Papadopoulou AK, Di Santo F, Antonarakis GS, Ghislanzoni LH Sildenafil and fetomaternal outcomes in pregnancy-associated pulmonary hypertension. Ann Pediatr Cardiol. 2026 Sep-Oct;19(5):623-624. doi: 10.4103/apc.apc_218_26. Epub 2026 Sep 8. Arun Babu T, Sharmila V Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis. Lancet Oncol. 2026 Oct;27(10):1237-1248. doi: 10.1016/S1470-2045(26)00307-4. Rumgay H, Georges D, Huang Y, Hirabayashi M, Shah R, de Martel C, Park JY, Soerjomataram I, Clifford GM Laryngopharyngeal reflux: The microbiota theory. Med Hypotheses. 2021 Jan;146:110460. doi: 10.1016/j.mehy.2020.110460. Epub 2020 Dec 16. Lechien JR, De Vos N, Everard A, Saussez S |
||